Vancouver, British Columbia, July 20, 1011 - Toronto based eResearch has issued a new research report on Microbix Biosystems (TSX:MBX), giving the company a speculative buy recommendation with a 12 month target price of $1.15, more than triple today`s price of $0.35.

InvestmentPitch.com has produced a "video news alert" based on the research report. If this link is not enabled, please visit www.investmentpitch.com and enter "Microbix" in the search box.

Microbix develops and commercializes biological products and technologies out of two facilities in the Greater Toronto area. Current products include a variety of infectious disease antigens, including flu and hepatitis viruses. The company sells about 40 different products to more than 11 companies globally, including names such as Pfizer, Seimens, and Abbott.

Management has taken a core virology business and used the proceeds this business has generated over the years, expected to be $5.8 million in 2011, and applied them to develop or acquire high-potential, large-market products to serve a variety of health-science segments. eResearch believes the company is now at the threshold and about to reap the benefits.

Flu vaccine production, which occurs in specially-prepared, fertilized chicken eggs, results in significant waste material. The company, with its VIRUSMAX(TM) product has developed a patented technology that liberates a significant amount of additional virus from this debris, greatly enhancing the yield of the virus.

This annual global vaccine market is estimated at about $28 billion, with flu vaccines at $7 billion, which could climb substantially if more countries, such as China, pursue a policy of inoculating their populations against the flu.

Mibrobix` need for a reliable supply of highly purified water prompted the company to develop what they call a water solutions product, which it has been selling since 2007. Microbix produces and sells filtered water-for-injection, in 20 to 200 litre quantities, for customers whose processes require highly purified water for such uses as production of tissue culture media, purification reagents, and facility cleaning.

The company is developing several exciting, large market products which should be commercially ready over the next 18 -24 months, and could put the company on a high-growth trajectory.

Every year, with more than 5 million patients in the United States having catheters placed into their bodies for providing dialysis treatment, for fighting infections with medications that need to be delivered intravenously, for providing nutrition, or for indications of oncology, the blood often clots at the opening of the catheter, which prevents them from functioning properly. This puts the patient in severe jeopardy, with approximately 1.5 million patients experiencing catheter-related thrombosis, as well as costing the industry up to $7,000 per patient to replace these catheters. The company`s blood clot-busting drug, KINLYTIC(TM), addresses both the catheter clearance and other potential markets.

Another large-market opportunity is the company`s innovative proprietary livestock artificial insemination technology, branded LumiSort(TM). LumiSort allows Microbix to differentiate livestock sperm between Y chromosomes, where offspring would result in a bull, and X chromosomes, where offspring would result in a heifer. The company`s technology allows for faster and more accurate sex determination.

With dairy heifers more valuable than dairy bulls, it is obviously desirable to deliver female offspring, especially if they come from strong milk-producing cows. The global dairy cattle market for artificial insemination, in OECD countries alone, is estimated at $1.4 billion, with about 200 million semen straws sold annually. In dairy farming, about 90% of reproduction is done through artificial insemination.

Microbix has a lead relationship with a global livestock artificial insemination firm that sells approximately 7 million straws globally, and has lined up four other firms which have expressed strong interest in using the LumiSort technology. The company anticipates this product will become a strong driver of revenue for the company going forward.

For a more information about Microbix Biosystems, please visit their website at www.microbix.com, or phone 416-234-1624.

For a copy of the report, contact eResearch at www.eresearch.ca. While on their site, sign up for their free reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com